<DOC>
	<DOCNO>NCT00646984</DOCNO>
	<brief_summary>Aim : To assess safety progression HIV infection efficacy evolution metabolic parameter body fat either viral load- CD4 cell-driven strategy intermittent treatment chronically HIV-1-infected person . Design : Pilot , prospective , open , randomize , control 3-year study . Setting patient : University hospital . Patients viral load &lt; 200 copies/mL CD4 cell count &gt; 450/mm3 least last 3 month . Three arm 50 patient , randomize either continue antiretroviral therapy , discontinue long either HIV-1 RNA low 30000 copies/mL CD4 cell count high 300/mm3 . Study end-points : evolution plasma metabolic parameter , body fat , bone mineral density ; incidence adverse effect due antiretroviral therapy symptom consistent acute retroviral syndrome ; incidence virological failure ( plasma HIV-1 RNA &gt; 200 copies/mL therapy ) , immunological failure ( CD4 cell count &lt; 200/mm3 therapy ) , clinical failure ( development AIDS-defining illness ) ; cost antiretroviral therapy administer time free therapy arm assign intermittent treatment ; evolution T lymphocyte subpopulation development proliferative cytotoxic response HIV .</brief_summary>
	<brief_title>Strategies Interruption/Reinitiation Antiretroviral Therapy HIV-Infected Patients With Lipodystrophy</brief_title>
	<detailed_description />
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>HIV-Associated Lipodystrophy Syndrome</mesh_term>
	<criteria>HIVinfected patient On stable antiretroviral therapy Viral load 200 copies/ml CD4 450 cells/mcl last 3 month Weight variation high 10 % compare previous stable weight Active ( CDCC ) opportunistic event Major depression schizophrenia psychiatric treatment Lack clinical stability Pregnant woman plan pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Lipodystrophy</keyword>
	<keyword>Treatment interruption</keyword>
	<keyword>HIV</keyword>
</DOC>